Literature DB >> 26221566

Confocal fluorescence microscopy: An ultra-sensitive tool used to evaluate intracellular antiretroviral nano-drug delivery in HeLa cells.

Subhra Mandal1, You Zhou2, Annemarie Shibata3, Christopher J Destache1.   

Abstract

In the last decade, confocal fluorescence microscopy has emerged as an ultra-sensitive tool for real-time study of nanoparticles (NPs) fate at the cellular-level. According to WHO 2007 report, Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) is still one of the world's major health threats by claiming approximately 7,000 new infections daily worldwide. Although combination antiretroviral drugs (cARV) therapy has improved the life-expectancy of HIV-infected patients, routine use of high doses of cARV has serious health consequences and requires complete adherence to the regimen for success. Thus, our research goal is to fabricate long-acting novel cARV loaded poly(lactide-co-glycolic acid) (PLGA) nanoparticles (cARV-NPs) as drug delivery system. However, important aspects of cARV-NPs that require special emphasis are their cellular-uptake, potency, and sustained drug release efficiency over-time. In this article, ultra-sensitive confocal microscopy is been used to evaluate the uptake and sustained drug release kinetics of cARV-NPs in HeLa cells. To evaluate with the above goal, instead of cARV-drug, Rhodamine6G dye (fluorescent dye) loaded NPs (Rho6G NPs) have been formulated. To correlate the Rhodamin6G release kinetics with the ARV release from NPs, a parallel HPLC study was also performed. The results obtained indicate that Rho6G NPs were efficiently taken up at low concentration (<500 ng/ml) and that release was sustained for a minimum of 4 days of treatment. Therefore, high drug assimilation and sustained release properties of PLGA-NPs make them an attractive vehicle for cARV nano-drug delivery with the potential to reduce drug dosage as well as the number of drug administrations per month.

Entities:  

Year:  2015        PMID: 26221566      PMCID: PMC4499042          DOI: 10.1063/1.4926584

Source DB:  PubMed          Journal:  AIP Adv            Impact factor:   1.548


  21 in total

1.  Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy.

Authors:  Mariko Horiike; Shingo Iwami; Makoto Kodama; Akihiko Sato; Yuji Watanabe; Mika Yasui; Yuki Ishida; Takeshi Kobayashi; Tomoyuki Miura; Tatsuhiko Igarashi
Journal:  Virology       Date:  2011-12-21       Impact factor: 3.616

2.  Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice.

Authors:  Christopher J Destache; Todd Belgum; Michael Goede; Annemarie Shibata; Michael A Belshan
Journal:  J Antimicrob Chemother       Date:  2010-08-21       Impact factor: 5.790

3.  Engineering cells with intracellular agent-loaded microparticles to control cell phenotype.

Authors:  James A Ankrum; Oscar R Miranda; Kelvin S Ng; Debanjan Sarkar; Chenjie Xu; Jeffrey M Karp
Journal:  Nat Protoc       Date:  2014-01-09       Impact factor: 13.491

4.  Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells.

Authors:  Murali Mohan Yallapu; Brij K Gupta; Meena Jaggi; Subhash C Chauhan
Journal:  J Colloid Interface Sci       Date:  2010-05-12       Impact factor: 8.128

5.  Development and validation of a simple and isocratic reversed-phase HPLC method for the determination of rilpivirine from tablets, nanoparticles and HeLa cell lysates.

Authors:  Abhijit A Date; Annemarie Shibata; Patrick Bruck; Christopher J Destache
Journal:  Biomed Chromatogr       Date:  2014-10-09       Impact factor: 1.902

6.  Mammalian cells preferentially internalize hydrogel nanodiscs over nanorods and use shape-specific uptake mechanisms.

Authors:  Rachit Agarwal; Vikramjit Singh; Patrick Jurney; Li Shi; S V Sreenivasan; Krishnendu Roy
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-07       Impact factor: 11.205

7.  Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy.

Authors:  Tae-Wook Chun; David C Nickle; Jesse S Justement; Jennifer H Meyers; Gregg Roby; Claire W Hallahan; Shyam Kottilil; Susan Moir; Joann M Mican; James I Mullins; Douglas J Ward; Joseph A Kovacs; Peter J Mannon; Anthony S Fauci
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

8.  Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier.

Authors:  Hirenkumar K Makadia; Steven J Siegel
Journal:  Polymers (Basel)       Date:  2011-08-26       Impact factor: 4.329

9.  Nanoparticle interactions with live cells: Quantitative fluorescence microscopy of nanoparticle size effects.

Authors:  Li Shang; Karin Nienhaus; Xiue Jiang; Linxiao Yang; Katharina Landfester; Volker Mailänder; Thomas Simmet; G Ulrich Nienhaus
Journal:  Beilstein J Nanotechnol       Date:  2014-12-11       Impact factor: 3.649

Review 10.  Engineered nanoparticles interacting with cells: size matters.

Authors:  Li Shang; Karin Nienhaus; Gerd Ulrich Nienhaus
Journal:  J Nanobiotechnology       Date:  2014-02-03       Impact factor: 10.435

View more
  8 in total

1.  An Enhanced Emtricitabine-Loaded Long-Acting Nanoformulation for Prevention or Treatment of HIV Infection.

Authors:  Subhra Mandal; Michael Belshan; Ashley Holec; You Zhou; Christopher J Destache
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

2.  Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission.

Authors:  Subhra Mandal; Pavan K Prathipati; Guobin Kang; You Zhou; Zhe Yuan; Wenjin Fan; Qingsheng Li; Christopher J Destache
Journal:  AIDS       Date:  2017-02-20       Impact factor: 4.177

3.  Targeted Immuno-Antiretroviral to Promote Dual Protection against HIV: A Proof-of-Concept Study.

Authors:  Subhra Mandal; Shawnalyn W Sunagawa; Pavan Kumar Prathipati; Michael Belshan; Annemarie Shibata; Christopher J Destache
Journal:  Nanomaterials (Basel)       Date:  2022-06-06       Impact factor: 5.719

4.  Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model.

Authors:  Pavan Kumar Prathipati; Subhra Mandal; Gregory Pon; Renuga Vivekanandan; Christopher J Destache
Journal:  Pharm Res       Date:  2017-09-13       Impact factor: 4.200

5.  Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model.

Authors:  Christopher J Destache; Subhra Mandal; Zhe Yuan; Guobin Kang; Abhijit A Date; Wuxun Lu; Annemarie Shibata; Rachel Pham; Patrick Bruck; Michael Rezich; You Zhou; Renuga Vivekanandan; Courtney V Fletcher; Qingsheng Li
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

6.  A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis.

Authors:  Subhra Mandal; Pavan Kumar Prathipati; Shawnalyn W Sunagawa; Christopher J Destache
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.938

Review 7.  The Pre-clinical Toolbox of Pharmacokinetics and Pharmacodynamics: in vitro and ex vivo Models.

Authors:  Carolina Herrera
Journal:  Front Pharmacol       Date:  2019-05-24       Impact factor: 5.810

8.  Cellulose Acetate Phthalate and Antiretroviral Nanoparticle Fabrications for HIV Pre-Exposure Prophylaxis.

Authors:  Subhra Mandal; Karl Khandalavala; Rachel Pham; Patrick Bruck; Marisa Varghese; Andrew Kochvar; Ashley Monaco; Pavan Kumar Prathipati; Christopher Destache; Annemarie Shibata
Journal:  Polymers (Basel)       Date:  2017-09-07       Impact factor: 4.329

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.